Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update
January 27, 2022 16:01 ET
|
Nurix Therapeutics, Inc.
Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 million Anticipate multiple...
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
January 10, 2022 07:00 ET
|
Nurix Therapeutics, Inc.
Nurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform ...
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting
December 12, 2021 09:00 ET
|
Nurix Therapeutics, Inc.
U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the blood‑brain barrier in preclinical models...
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
November 12, 2021 07:09 ET
|
Nurix Therapeutics, Inc.
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) --...
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
November 12, 2021 07:07 ET
|
Nurix Therapeutics, Inc.
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix’s chief cellular...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
November 09, 2021 16:01 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
October 27, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of...
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
October 26, 2021 16:02 ET
|
Nurix Therapeutics, Inc.
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE...
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
October 21, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s...